158 related articles for article (PubMed ID: 30308053)
1. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
Uchida Y; Naiki K; Kouyama JI; Sugawara K; Nakao M; Motoya D; Inao M; Nakayama N; Imai Y; Tomiya T; Mochida S
PLoS One; 2018; 13(10):e0205600. PubMed ID: 30308053
[TBL] [Abstract][Full Text] [Related]
2. Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination.
Tamori A; Hai H; Uchida-Kobayashi S; Enomoto M; Kozuka R; Motoyama H; Kawamura E; Hagihara A; Teranishi Y; Yoshida K; Morikawa H; Murakami Y; Kawada N
Ann Hepatol; 2017; 16(5):734-741. PubMed ID: 28809743
[TBL] [Abstract][Full Text] [Related]
3. Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
Akuta N; Sezaki H; Suzuki F; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2016 Mar; 88(3):506-11. PubMed ID: 26292191
[TBL] [Abstract][Full Text] [Related]
4. Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.
Akuta N; Sezaki H; Suzuki F; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Jan; 89(1):91-98. PubMed ID: 27256744
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
Morio R; Imamura M; Kawakami Y; Morio K; Kobayashi T; Yokoyama S; Kimura Y; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Nelson Hayes C; Aikata H; Takahashi S; Miki D; Ochi H; Mori N; Takaki S; Tsuji K; Chayama K
J Gastroenterol; 2017 Apr; 52(4):504-511. PubMed ID: 27631593
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.
Suzuki F; Hatanaka N; Bando E; Nakamura K; Komoto A
Hepatol Int; 2018 May; 12(3):244-253. PubMed ID: 29900486
[TBL] [Abstract][Full Text] [Related]
7. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
[TBL] [Abstract][Full Text] [Related]
8. Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety.
Lee HW; Oh SR; Kim DY; Jeong Y; Kim S; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
Gut Liver; 2018 May; 12(3):324-330. PubMed ID: 29409309
[TBL] [Abstract][Full Text] [Related]
9. Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.
Kato K; Shimada N; Atsukawa M; Abe H; Itokawa N; Matsumoto Y; Agata R; Tsubota A
PLoS One; 2019; 14(7):e0219022. PubMed ID: 31291311
[TBL] [Abstract][Full Text] [Related]
10. Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation.
Harada N; Yoshizumi T; Ikegami T; Itoh S; Furusho N; Kato M; Shimoda S; Fukuhara T; Soejima Y; Maehara Y
Anticancer Res; 2018 Sep; 38(9):5513-5520. PubMed ID: 30194210
[TBL] [Abstract][Full Text] [Related]
11. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
Morio K; Imamura M; Kawakami Y; Morio R; Kobayashi T; Yokoyama S; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Makokha GN; Hayes CN; Aikata H; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
J Gastroenterol Hepatol; 2017 Mar; 32(3):645-650. PubMed ID: 27513614
[TBL] [Abstract][Full Text] [Related]
12. Sustained virological response after a 17-day treatment with daclatasvir plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype 1b and null response for peginterferon ribavirin therapy.
Sato A; Ishii T; Adachi K; Kumon D; Tamura T; Noguchi Y; Matsumoto N; Okuse C
Clin J Gastroenterol; 2016 Apr; 9(2):89-92. PubMed ID: 26896968
[TBL] [Abstract][Full Text] [Related]
13. High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
McPhee F; Suzuki Y; Toyota J; Karino Y; Chayama K; Kawakami Y; Yu ML; Ahn SH; Ishikawa H; Bhore R; Zhou N; Hernandez D; Mendez P; Kumada H
Adv Ther; 2015 Jul; 32(7):637-49. PubMed ID: 26155891
[TBL] [Abstract][Full Text] [Related]
14. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
Wei L; Zhang M; Xu M; Chuang WL; Lu W; Xie W; Jia Z; Gong G; Li Y; Bae SH; Yang YF; Xie Q; Lin S; Chen X; Niu J; Jia J; Garimella T; Torbeyns A; McPhee F; Treitel M; Yin PD; Mo L
J Gastroenterol Hepatol; 2016 Nov; 31(11):1860-1867. PubMed ID: 27003037
[TBL] [Abstract][Full Text] [Related]
15. Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study.
Shin SK; Lee JW; Ra H; Kwon OS; Shin JB; Jin YJ; Lee S; Han KJ; Kim YN; Kim TH; Kim YS; Kim JH
J Korean Med Sci; 2019 Oct; 34(41):e264. PubMed ID: 31650719
[TBL] [Abstract][Full Text] [Related]
16. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
Yu JH; Lee JI; Lee KS; Kim JK
Virol J; 2017 Aug; 14(1):164. PubMed ID: 28836992
[TBL] [Abstract][Full Text] [Related]
17. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
Yoshimi S; Imamura M; Murakami E; Hiraga N; Tsuge M; Kawakami Y; Aikata H; Abe H; Hayes CN; Sasaki T; Ochi H; Chayama K
J Med Virol; 2015 Nov; 87(11):1913-20. PubMed ID: 25954851
[TBL] [Abstract][Full Text] [Related]
18. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
Hong CM; Liu CJ; Yeh SH; Chen PJ
J Formos Med Assoc; 2017 Apr; 116(4):295-299. PubMed ID: 28034492
[TBL] [Abstract][Full Text] [Related]
19. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.
Kao JH; Lee YJ; Heo J; Ahn SH; Lim YS; Peng CY; Chang TT; Torbeyns A; Hughes E; Bhore R; Noviello S
Liver Int; 2016 Oct; 36(10):1433-41. PubMed ID: 27009831
[TBL] [Abstract][Full Text] [Related]
20. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]